<DOC>
	<DOC>NCT01864759</DOC>
	<brief_summary>The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally replicative or oncolytic adenovirus.</brief_summary>
	<brief_title>Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<criteria>Malignant melanoma advanced or metastatic. Other than 18 years Karnofsky index &gt; 60 % Life expectancy &gt; 3 months ALT/AST &lt;=2.5 times the upper normal limit Creatinine clearance &gt;= 50 ml/min. Bilirubin &lt;25 umol/l Alkaline phosphatase &lt;= 2.5 time upper normal limit Normal bone marrow function: Neutrophils &gt;=1.5 E9/L, platelets &gt;= 1E11/L, hemoglobin &gt;= 100 g/l, Normal prothrombin time and thromboplastin time, HIV negative Measurable disease Signed informed consent. Geographical, social or psychological conditions that may impair the protocol compliance. Active infections or other severe medical status. History of liver disease. Other or concomitant treatments for melanoma or investigational product. Previous participation in studies with adenovirus. Virus diseases diagnosed two weeks before inclusion. Immunosuppressive concomitant treatments Concomitant malignant haematological disease. Patients having family members with immunodeficient status or disease Patients with Li Fraumeni syndrome or germinal retinoblastoma gene defects.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>melanoma</keyword>
	<keyword>oncolytic</keyword>
	<keyword>adenovirus</keyword>
	<keyword>virotherapy</keyword>
	<keyword>locally advanced</keyword>
	<keyword>metastatic</keyword>
</DOC>